Zobrazeno 1 - 10 of 667 pro vyhledávání: '"Telliez JB"'
1
Akademický článek
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Autor: Martin DA; Pfizer Inc., Cambridge, MA, USA., Telliez JB; Pfizer Inc., Cambridge, MA, USA., Pleasic-Williams S; Pfizer Inc., Groton, CT, USA., Zhang Y; Pfizer Inc., Groton, CT, USA., Tierney B; Pfizer Inc., Groton, CT, USA., Blatnik M; Pfizer Inc., Groton, CT, USA., Gale JD; Pfizer Inc., Cambridge, MA, USA., Banfield C; Pfizer Inc., Cambridge, MA, USA., Zhou Y; Pfizer Inc., Collegeville, PA, USA., Lejeune A; Pfizer Inc., Paris, France., Zwillich SH; Pfizer Inc., Groton, CT, USA., Stevens E; Pfizer Inc., Groton, CT, USA., Tiwari N; Pfizer Inc., New Haven, CT, USA., Kieras E; Pfizer Inc., Cambridge, MA, USA., Karanam A; Pfizer Inc., Cambridge, MA, USA.
Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Jan; Vol. 64 (1), pp. 67-79. Date of Electronic Publication: 2023 Sep 29.
Zobrazit plný text záznamu
2
Akademický článek
JAK inhibitor selectivity: new opportunities, better drugs?
Autor: Virtanen A; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Spinelli FR; Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza Universitá di Roma, Rome, Italy., Telliez JB; Inflammation and Immunology, Pfizer, Cambridge, MA, USA., O'Shea JJ; Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA., Silvennoinen O; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Fimlab laboratories, Tampere, Finland., Gadina M; Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. gadinama@nih.gov.
Publikováno v: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2024 Oct; Vol. 20 (10), pp. 649-665. Date of Electronic Publication: 2024 Sep 09.
Zobrazit plný text záznamu
3
Akademický článek
Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Autor: Passeron T; University Côte d'Azur, Centre Hospitalier Universitaire Nice, Department of Dermatology, Nice, France.; University Côte d'Azur, INSERM, U1065, C3M, Nice, France., King B; Department of Dermatology, Yale University School of Medicine, New Haven, CT, United States., Seneschal J; Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin Diseases, Saint-André Hospital, University of Bordeaux, Bordeaux, France.; Bordeaux University, Centre national de la recherche scientifique (CNRS), ImmunoConcept, UMR5164, Bordeaux, France., Steinhoff M; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.; Department of Dermatology and Venereology, Weill Cornell Medicine-Qatar, Doha, Qatar.; College of Medicine, Qatar University, Doha, Qatar.; Department of Dermatology, Weill Cornell Medicine, New York, NY, United States.; College of Health and Life Sciences, Hamad Bin Khalifa University-Qatar, Doha, Qatar., Jabbari A; Department of Dermatology, University of Iowa, Iowa City, IA, United States.; Iowa City VA Medical Center, Iowa City, IA, United States., Ohyama M; Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan., Tobin DJ; Charles Institute of Dermatology, UCD School of Medicine, University College Dublin, Dublin, Ireland., Randhawa S; Pfizer Inc, New York, NY, United States., Winkler A; Pfizer Inc, Cambridge, MA, United States., Telliez JB; Pfizer Inc, Cambridge, MA, United States., Martin D; Pfizer Inc, Cambridge, MA, United States., Lejeune A; Pfizer Inc, Paris, France.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Nov 06; Vol. 14, pp. 1243556. Date of Electronic Publication: 2023 Nov 06 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Editorial & Opinion
Editorial: JAK inhibition in autoimmune and inflammatory diseases.
Autor: Telliez JB; Inflammation and Immunology, Pfizer, Cambridge, MA, United States., Gadina M; Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States., Ghoreschi K; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Silvennoinen O; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Spinelli FR; Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza Universitá di Roma, Roma, Italy.
Publikováno v: Frontiers in immunology [Front Immunol] 2022 Dec 28; Vol. 13, pp. 1120281. Date of Electronic Publication: 2022 Dec 28 (Print Publication: 2022).
Zobrazit plný text záznamu
5
Akademický článek
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Autor: Bauman JN; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Doran AC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., King-Ahmad A; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Sharma R; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Walker GS; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Lin J; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Lin TH; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Telliez JB; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Tripathy S; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Goosen TC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Banfield C; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Malhotra BK; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Dowty ME; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.) martin.dowty@pfizer.com.
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Aug; Vol. 50 (8), pp. 1106-1118. Date of Electronic Publication: 2022 Jun 14.
Zobrazit plný text záznamu
6
Akademický článek
Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.
Autor: Lee SD; Digestive Health Center, University of Washington Medical Center, Seattle, WA., Shivashankar R; Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia., Quirk D; Pfizer Inc., Cambridge, MA., Zhang H; Pfizer Inc., Collegeville, PA., Telliez JB; Pfizer Inc., Cambridge, MA., Andrews J; Pfizer Inc., Cambridge, MA., Marren A; Pfizer Inc., Cambridge, MA., Mukherjee A; Pfizer Inc., Groton, CT., Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Publikováno v: Journal of clinical gastroenterology [J Clin Gastroenterol] 2021 Mar 01; Vol. 55 (3), pp. 195-206.
Zobrazit plný text záznamu
7
Akademický článek
What to do when traditional rescue therapies fail in acute severe ulcerative colitis.
Autor: Li Wai Suen, Christopher F. D.1,2, Choy, Matthew C.1,2, De Cruz, Peter1,2 ppdecruz@gmail.com
Publikováno v: Intestinal Research. Oct2024, Vol. 22 Issue 4, p397-413. 17p.
Zobrazit plný text záznamu
8
Akademický článek
The advantages of describing covalent inhibitor in vitro potencies by IC 50 at a fixed time point. IC 50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization.
Autor: Thorarensen A; Medicine Design, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA. Electronic address: Atli.Thorarensen@pfizer.com., Balbo P; Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA., Banker ME; Medicine Design, Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340 USA., Czerwinski RM; Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA., Kuhn M; Research Statistics, Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340 USA., Maurer TS; Medicine Design, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA., Telliez JB; Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA., Vincent F; Medicine Design, Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340 USA., Wittwer AJ; Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, MA 02139 USA.
Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2021 Jan 01; Vol. 29, pp. 115865. Date of Electronic Publication: 2020 Nov 18.
Zobrazit plný text záznamu
9
Akademický článek
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
Autor: Yoon, Hyuk1 (AUTHOR), Ye, Byong Duk2 (AUTHOR), Kang, Sang-Bum3 (AUTHOR), Lee, Kang-Moon4 (AUTHOR), Choi, Chang Hwan5 (AUTHOR), Jo, Joo-young6 (AUTHOR), Woo, Juwon6 (AUTHOR), Cheon, Jae Hee7 (AUTHOR) geniushee@yuhs.ac
Publikováno v: BMC Gastroenterology. 8/19/2024, Vol. 24, p1-11. 11p.
Zobrazit plný text záznamu
10
Akademický článek
Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease.
Autor: Baoxin Zheng1, Liping Wang1, Yan Yi1, Jun Yin2, Aihua Liang1 ahliang@icmm.ac.cn
Publikováno v: Asian Journal of Pharmaceutical Sciences. Aug2024, Vol. 19 Issue 4, p1-29. 29p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje